A novel "priming-boosting" strategy for immune interventions in cervical cancer.

•Prediction and test HPV16 E5, E6 and E7 for MHC class I ligands and TAP binding affinity.•A short-term long-peptide (ST-LP) vaccine simultaneously covered three key carcinogenes epitopes of HPV16.•The new recombination AAV encoding the predicted epitopes of ST-LP as long-term long-peptide (LT-LP) vaccine.•A creative immune strategy by priming immune-system with ST-LP vaccine followed by boosting immune-system with LT-LP vaccine.•A new vaccine for both preventing and treating cervical cancer and the pre-cancerous lesions.